10-K: GRI Bio Reports Positive Phase 2a IPF Data, Faces Going Concern

GRI Bio, Inc. announced positive topline results from its Phase 2a clinical trial for GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), while also disclosing substantial doubt about its ability to continue as a going concern.

Summary

• GRI Bio is a clinical-stage biopharmaceutical company focused on therapies for inflammatory, fibrotic, and autoimmune disorders.
• The company's lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells, being developed for severe fibrotic lung diseases like Idiopathic Pulmonary Fibrosis (IPF).
• Topline results from a randomized, double-blind, multi-center Phase 2a clinical trial for GRI-0621 in IPF patients met its primary endpoint of safety and tolerability, and secondary endpoints measured to date.
• No treatment-related serious adverse events were reported for GRI-0621-treated subjects; common adverse events were dry skin, dry lips, muscle and joint pain (Grade 2: 17%, Grade 3: 4%).
• GRI-0621 treatment showed suggestive anti-fibrotic effects, including decreases in fibrosis formation biomarkers and increases in fibrosis resolution biomarkers (e.g., crosslinked type III collagen).
• Changes in type IV collagen suggested initiation of alveolar basement membrane repair.
• Reductions in neutrophil and macrophage activity and downregulation of genes associated with fibrosis, disease progression, and mortality were observed.
• Placebo-adjusted Forced Vital Capacity (FVC) increased by 99 ml in the GRI-0621 arm, and by 139 ml in the subset taking both GRI-0621 and standard of care.
• A post hoc analysis, excluding FVC outliers, showed an increase of 54 ml in the GRI-0621 arm and 81 ml in the subset with standard of care.
• 39% of GRI-0621 treated subjects experienced an increase in FVC at 12 weeks, compared to 80% of placebo subjects who experienced a decline.
• GRI-0621 also demonstrated increased TCR expression, suggestive of iNKT inactivation, and a shift in T cell subsets towards anti-inflammatory cytokines.
• The company plans to initiate a Phase 2b trial for GRI-0621, potentially supporting conditional approval in the EU and a registrational trial in the US, subject to FDA clearance and additional funding.
• GRI-0803, a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells, is being developed for autoimmune disorders like Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS).
• Preclinical studies for GRI-0803 showed potential therapeutic benefits in models of autoimmunity, including inhibition of lupus nephritis and improved survival in mice.
• The company intends to complete IND-enabling studies and file an IND application for GRI-0803 in 2026 to evaluate it in Phase 1a and 1b trials in healthy volunteers.
• GRI Bio reported a net loss of $12.0 million for the year ended December 31, 2025, compared to $8.2 million for 2024.
• As of December 31, 2025, cash and cash equivalents were $8.2 million, with an accumulated deficit of $51.7 million.
• Management believes existing cash will fund operations into Q1 2027, but substantial additional capital is required to complete a Phase 2b trial for GRI-0621.
• The company's independent auditors included explanatory paragraphs regarding substantial doubt about its ability to continue as a going concern.
• GRI Bio completed several capital raises in 2024 and 2025, including public offerings and an At-The-Market (ATM) offering, raising significant net proceeds.
• A one-for-28 reverse stock split was effected on January 23, 2026, with post-split trading beginning January 26, 2026, to maintain Nasdaq listing compliance.
• The company has a material weakness in internal controls over financial reporting related to accounting software limitations and limited accounting personnel, leading to insufficient segregation of duties.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the positive Phase 2a data for GRI-0621 is a significant clinical milestone, the company's persistent 'going concern' warning and substantial need for additional capital introduce considerable financial risk and uncertainty for investors.

Positives

• GRI-0621 Phase 2a trial met its primary endpoint of safety and tolerability in IPF patients, with no treatment-related serious adverse events.
• Adverse events for GRI-0621 were generally mild (dry skin, dry lips, muscle and joint pain) and consistent with known effects of tazarotene.
• GRI-0621 showed suggestive anti-fibrotic effects, including decreases in fibrosis formation biomarkers and increases in fibrosis resolution biomarkers.
• Observed changes in type IV collagen suggest initiation of alveolar basement membrane repair, a crucial step in lung tissue healing.
• Reductions in neutrophil and macrophage activity, and downregulation of fibrosis-associated genes, were noted in GRI-0621 treated patients.
• Placebo-adjusted FVC increased by 99 ml in the GRI-0621 arm, and by 139 ml in the subset receiving standard of care, indicating potential lung function improvement.
• Post hoc analysis of FVC data, excluding outliers, still showed increases of 54 ml and 81 ml, respectively, in the GRI-0621 arms.
• 39% of GRI-0621 treated subjects experienced an increase in FVC, contrasting with 80% of placebo subjects experiencing a decline.
• GRI-0621 treatment suggested iNKT inactivation and a favorable shift in T cell cytokine profiles (increased type 1, reduced type 2 and 3).
• Preclinical data for GRI-0803 in autoimmune models (lupus nephritis) showed inhibition of pro-inflammatory cytokines (IL-17, IL-6), TGF-beta, collagen deposition, and improved overall survival.
• The company has retained global development and commercialization rights for all its product candidates.
• Successful capital raises in 2024 and 2025, including public offerings and an ATM facility, provided $13.4 million in net cash from financing activities in 2025.

Negatives

• GRI Bio has incurred significant net losses since inception, with a net loss of $12.0 million in 2025 and an accumulated deficit of $51.7 million.
• The company has expressed substantial doubt about its ability to continue as a going concern, and auditors have included explanatory paragraphs regarding this uncertainty.
• Existing cash and cash equivalents are only sufficient to fund operations into Q1 2027, with substantial additional capital needed to complete the planned Phase 2b trial for GRI-0621.
• The previous pilot Phase 2a trial for GRI-0621 in liver disease patients was halted due to recruitment challenges and updated FDA guidance, and was underpowered to meet endpoints with statistical significance.
• The company has a limited operating history and no products approved for commercial sale.
• The stock price has been highly volatile, and previous reverse stock splits have reduced liquidity.
• The company has exceeded Nasdaq's limits on reverse stock splits for eligibility for compliance periods, increasing delisting risk if the Minimum Bid Price Rule is violated again.
• A material weakness in internal controls over financial reporting exists due to accounting software limitations and limited accounting personnel, leading to insufficient segregation of duties.
• The company relies heavily on third-party CROs and manufacturers, exposing it to risks of delays, quality issues, and supply chain disruptions.
• Competition in the biotechnology and biopharmaceutical industries is intense, with many larger companies having greater resources.

Risks

• Incurring significant net losses for the foreseeable future and never achieving profitability.
• Requiring substantial additional capital to finance operations, particularly to complete a Phase 2b clinical trial of GRI-0621, and inability to raise such capital on acceptable terms or at all.
• Utilizing cash and available resources faster than expected, with current estimates not including costs for completing a Phase 2b trial of GRI-0621.
• Inability to continue as a going concern if additional financing is not obtained.
• High dependence on the success of product candidates (GRI-0621 and GRI-0803), which require significant additional development and may encounter safety, efficacy, or regulatory problems.
• Clinical development being a lengthy, complex, expensive, and uncertain process, with preclinical and early-stage results not predictive of later-stage outcomes.
• Interim, topline, and preliminary data from clinical trials (including GRI-0621 Phase 2a) may change as more data become available and are subject to audit and verification.
• Failure to obtain or maintain adequate reimbursement or insurance coverage for approved product candidates, limiting marketability and revenue generation.
• Inability to obtain approval or commercialize product candidates outside the United States, limiting full market potential.
• Inability to enter into beneficial collaborations with third parties for development and commercialization, or failure of such collaborations.
• Difficulty and cost in protecting intellectual property, with no assurance of patent protection or enforceability against third-party challenges.
• Reliance on third parties to conduct clinical trials, manufacture product candidates, and perform other services, with risks of non-compliance, delays, or termination of agreements.
• Loss of key management personnel or failure to recruit and retain highly skilled personnel, impairing development capabilities and competitiveness.
• Inability to adequately protect internal information systems or those of third parties from cyberattacks, leading to data compromise, operational disruption, reputational harm, and financial/legal exposure.
• Future sales and issuances of securities could result in additional dilution and cause share price to fall.
• The January 2026 Reverse Stock Split may cause stock price decline and reduced liquidity.
• Significant increased costs and management time devoted to compliance initiatives as a public company.
• Ineffectiveness of internal controls over financial reporting due to material weaknesses, impairing ability to produce accurate financial statements.
• Adverse effects from health pandemics or epidemics on operations, third-party facilities, and supply chains.
• Inadequate insurance coverage against potential claims.
• Potential for stockholder derivative or class-action litigations, diverting resources and incurring significant expenses.
• Charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.
• Changes in tax law could adversely affect the business.
• An active trading market for Common Stock may not develop, making it difficult for stockholders to resell shares.
• Lack of equity research analyst coverage or unfavorable reports could cause stock price and trading volume to decline.
• Uncertainty regarding the FDA's Section 505(b)(2) pathway for GRI-0621, potentially leading to longer, more costly, and riskier development.
• Failure to obtain Fast Track designation or other expedited review programs, or such designations not leading to faster processes.
• Ongoing regulatory obligations and continued review post-approval, leading to significant expenses and potential penalties for non-compliance.
• Failure of approved product candidates to achieve market acceptance by physicians, patients, and third-party payors.
• Government and other third-party payors not providing adequate coverage and reimbursement levels for products.
• Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, with serious consequences for violations.
• Failure to comply with environmental, health, and safety laws and regulations, leading to fines or penalties.
• Expiration of patents before or soon after products are approved or commercialized, diminishing value of patent protection.
• Changes in patent law in the United States and foreign jurisdictions diminishing the value of patents.
• Limited foreign intellectual property rights and inability to protect and enforce them globally.
• Inability to obtain or maintain necessary rights to develop future product candidates on acceptable terms from third parties.

Future Outlook

GRI Bio plans to initiate a Phase 2b trial for GRI-0621, which could potentially support conditional approval in the European Union and be considered a registrational trial in the United States, subject to FDA clearance and securing additional funding. For GRI-0803, the company intends to complete IND-enabling studies and file an IND application in 2026 to evaluate it in Phase 1a and 1b trials in healthy volunteers, with an initial focus on lupus. The company expects to continue incurring significant operating losses and will require substantial additional capital to fund its future operations beyond Q1 2027.

Management Comments

• Management has expressed substantial doubt about our ability to continue as a going concern.
• Management expects to continue to incur significant losses for the foreseeable future, and anticipates that expenses will increase substantially as product candidates advance through clinical development.
• Management expects to continue to utilize the compensating controls in place to mitigate the segregation of duty weakness and will seek to improve on such controls as reasonably possible, until such time as our resources allow for further remediation.

Industry Context

StockSavvy.ai notes that GRI Bio operates in the highly competitive and rapidly evolving biopharmaceutical sector, targeting significant unmet medical needs in inflammatory, fibrotic, and autoimmune disorders. The IPF market, while therapeutically underserved, has existing approved therapies (nintedanib, pirfenidone, nerandomilst) that face adherence issues due to side effects. GRI-0621's mechanism of inhibiting iNKT cells offers a differentiated approach compared to current treatments, which could be a competitive advantage if clinical success continues. The SLE market also has high unmet needs, with only two drugs approved in the last 50 years, positioning GRI-0803 as a potential new option. The company's reliance on third-party manufacturing and CROs is standard for early-to-mid-stage biotechs but introduces supply chain and quality control risks. The ongoing scrutiny of drug pricing and PBM practices, along with the Inflation Reduction Act, presents a challenging reimbursement landscape for future commercialization.

Comparison to Industry Standards

• GRI-0621's observed safety profile in the Phase 2a IPF trial, with no treatment-related serious adverse events and common adverse events being mild, appears favorable compared to existing IPF therapies like nintedanib (OFEV) and pirfenidone (Esbriet), which are associated with significant side effects (e.g., >60% diarrhea for nintedanib, ~30% skin rash for pirfenidone) leading to poor therapeutic adherence and high discontinuation rates.
• The reported FVC increases in GRI-0621 treated patients (99 ml placebo-adjusted, or 54 ml in post hoc analysis) suggest a potential benefit in lung function, which is a key measure in IPF. While direct statistical comparison to approved therapies is not provided for this Phase 2a data, existing therapies primarily slow decline rather than improve overall survival, indicating a high unmet need for disease-modifying treatments.
• The company's strategy to target iNKT cells for IPF and dNKT cells for autoimmune disorders like SLE represents a novel approach, differentiating it from competitors like AbbVie, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline, which are developing products for these conditions but may not specifically target NKT cells.
• GRI Bio's financial position, with an accumulated deficit of $51.7 million and auditors expressing substantial doubt about going concern, is typical for clinical-stage biopharmaceutical companies that are pre-revenue and heavily investing in R&D, but it highlights significant financial risk compared to more established, profitable industry players.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that could have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Employment agreements with executive officers provide for base salary, annual cash bonuses, and certain termination benefits.
• Stock options have been granted to executive officers and members of the Board.
• The company has indemnification agreements with each of its directors and officers, providing for indemnification to the fullest extent permitted by Delaware law and advancement of expenses.
• The company's obligations to indemnify directors/officers are primary, with any indemnification from their affiliates or other third parties being secondary.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and potential stock price volatility. The 'going concern' warning and material weakness in internal controls pose substantial risks to investment value. Positive clinical data for GRI-0621 could provide upside, but commercialization is distant and uncertain.
• **Employees:** The company's ability to attract and retain highly skilled personnel is critical for R&D success. The 'going concern' status could impact employee morale and retention. Executive compensation includes equity awards, aligning interests with stock performance.
• **Patients (IPF):** GRI-0621 offers a potential new therapeutic option with a differentiated mechanism and a favorable safety profile compared to existing treatments, potentially improving outcomes for a life-threatening disease.
• **Patients (SLE/Autoimmune):** GRI-0803 represents a promising preclinical candidate for autoimmune disorders, addressing a high unmet need for new treatments.
• **Creditors/Suppliers:** The 'going concern' warning indicates increased credit risk. The company's reliance on third-party manufacturers and CROs means their financial health and operational stability are indirectly tied to GRI Bio's ability to secure funding.
• **Regulatory Bodies (FDA, Nasdaq):** The company is actively engaging with the FDA for clinical trial design and approval pathways. Compliance with Nasdaq listing requirements is an ongoing challenge, as evidenced by recent reverse stock splits and compliance notices.

Next Steps

• Determine dose, safety sample size, clinically relevant endpoints, and clinical trial duration for future GRI-0621 trials in communication with the FDA.
• Initiate (either independently or with a strategic partner) a Phase 2b trial for GRI-0621, subject to FDA clearance and obtaining requisite additional funding or resources.
• Complete IND-enabling studies for GRI-0803.
• File an IND application for GRI-0803 in 2026 to evaluate it in a Phase 1a and 1b trial in healthy volunteers.
• Continue to evaluate indications to select the best fit for further development of the GRI-0803 program, with an initial focus on lupus.
• Seek to improve compensating controls for the identified material weakness in internal controls over financial reporting, and potentially retain additional accounting personnel or procure alternative accounting software if resources allow.

Key Dates

Recommendation

While the positive Phase 2a clinical trial results for GRI-0621 in IPF are encouraging and represent a significant scientific milestone, the company's severe financial distress, including a 'going concern' warning from auditors and limited cash runway into Q1 2027, presents an overwhelming risk. The need for substantial additional capital to complete the next phase of clinical trials, coupled with a history of significant losses and multiple reverse stock splits to maintain Nasdaq listing, indicates a high probability of further dilution and continued stock price volatility. The identified material weakness in internal controls further exacerbates the risk profile. Given these factors, the financial risks currently outweigh the clinical promise, making it a 'sell' for seasoned investors.

Keywords

Biopharmaceutical, Clinical-stage, IPF, Idiopathic Pulmonary Fibrosis, GRI-0621, iNKT cells, Autoimmune disorders, SLE, Systemic Lupus Erythematosus, GRI-0803, dNKT cells, Fibrotic diseases, Inflammatory diseases, Drug development, Clinical trials, SEC filing, Nasdaq, Reverse stock split, Capital raise, Going concern, Tazarotene